Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan

Publication Date

6-2-2024

Presented At:

American Society of Clinical Oncology (ASCO) Annual Meeting

This document is currently not available here.

Share

COinS